Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Long-Term Debt Repayments (2018 - 2025)

Guided Therapeutics (GTHP) has disclosed Long-Term Debt Repayments for 8 consecutive years, with $187000.0 as the latest value for Q4 2025.

  • Quarterly Long-Term Debt Repayments fell 6.03% to $187000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $499000.0 through Dec 2025, up 13.93% year-over-year, with the annual reading at $499000.0 for FY2025, 13.93% up from the prior year.
  • Long-Term Debt Repayments hit $187000.0 in Q4 2025 for Guided Therapeutics, up from $94000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $811000.0 in Q2 2021 to a low of $41000.0 in Q2 2023.
  • Historically, Long-Term Debt Repayments has averaged $180944.4 across 5 years, with a median of $116500.0 in 2024.
  • Biggest five-year swings in Long-Term Debt Repayments: crashed 94.7% in 2022 and later skyrocketed 342.22% in 2024.
  • Year by year, Long-Term Debt Repayments stood at $811000.0 in 2021, then crashed by 90.75% to $75000.0 in 2022, then crashed by 40.0% to $45000.0 in 2023, then surged by 342.22% to $199000.0 in 2024, then fell by 6.03% to $187000.0 in 2025.
  • Business Quant data shows Long-Term Debt Repayments for GTHP at $187000.0 in Q4 2025, $94000.0 in Q3 2025, and $71000.0 in Q2 2025.